Skip to the main content

Signa vitae : journal for intesive care and emergency medicine, Vol. 5 No. 1, 2010.

Review article

Human protein C concentrate in pediatric septic patients

GIOVANNI LANDONI orcid id orcid.org/0000-0002-8594-5980 ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
GIACOMO MONTI ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
ALBERTO FACCHINI ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
FRANCESCO CAMA ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
ELENA BIGNAMI ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
LUCA CABRINI ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
FEDERICO PAPPALARDO ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
ALBERTO ZANGRILLO ; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy

Full text: english pdf 50 Kb

page 13-19

downloads: 816

cite

Abstract

Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. Unlike what is suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children. Long before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C zymogen. Therefore, we conducted a systemic review of currently available data on protein C zymogen (PC) use among children affected by severe sepsis or septic shock.
A total number of 13 case series or case reports and a dose-finding study were found on the use of PC in the pediatric intensive care unit, reporting on 118 treated children, with an overall survival of 84%. There was no bleeding complication, the only reported complication being a single mild allergic reaction. These studies show that PC is safe, not associated with bleeding and possibly useful for improving coagulation abnormalities of sepsis.

Keywords

sepsis; pediatric; protein C; drug therapy; review

Hrčak ID:

51529

URI

https://hrcak.srce.hr/51529

Publication date:

1.4.2010.

Visits: 1.651 *